Department of Imaging, Tongren Hospital, Shanghai Jiao Tong University School of Medicine, 1111 Xian Xia Road, Shanghai, 200050, China.
Department of Radiology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, 600 Yi Shan Road, Shanghai, 200233, China.
BMC Musculoskelet Disord. 2020 Jan 29;21(1):53. doi: 10.1186/s12891-020-3063-5.
Chondromyxoid fibroma-like osteosarcoma (CMF-OS) is an exceedingly rare subtype of low-grade central osteosarcoma (LGCO), accounting for up to 10% of cases and making it difficult to diagnose. CMF-OS is frequently misdiagnosed on a radiological examination and biopsy, even after the initial operation. Its treatment is a controversial issue due to its low-grade classification and actual high-grade behavior.
We retrospectively reviewed the medical charts of more than 2000 osteosarcoma patients between 2008 and 2019; 11 patients with CMF-OS were identified, of which six patients were treated by our institution with complete clinical characteristics, including treatment and prognosis, radiological and pathological features were reviewed. Three males and three females with a median age of 46 (range 22-56) years were pathologically proven to have CMF-OS. The radiological presentation of CMF-OS is variable, thus radiological misdiagnoses are common. However, one must not ignore a malignant radiologic appearance. The most distinctive pathological feature conferring the diagnosis of CMF-OS is the presence of osteoid production directly by the tumor cells under a chondromyxoid fibroma (CMF)-like background. Differential diagnoses based on comprehensive data from CMF, LGCO, chondrosarcoma (CHS), conventional osteosarcoma (COS), etc., are needed. All patients were treated with an operation and chemotherapy, and one patient received additional radiotherapy. Nevertheless, recurrence and metastasis are common in CMF-OS patients. Relatively invasive biological behavior of CMF-OS is against the low-grade classification of this disease.
It is important to recognize CMF-OS and distinguish it from CMF, CHS, COS and other LGCOs. CMF-OS has a relatively poor prognosis despite its low-grade classification.
软骨黏液样纤维瘤样骨肉瘤(CMF-OS)是一种罕见的低级中央型骨肉瘤(LGCO)亚型,占比高达 10%,难以诊断。CMF-OS 在影像学检查和活检时经常被误诊,即使在初次手术后也是如此。由于其低级分类和实际的高级行为,其治疗是一个有争议的问题。
我们回顾性分析了 2008 年至 2019 年间 2000 多名骨肉瘤患者的病历,发现了 11 例 CMF-OS 患者,其中 6 例在我院接受了治疗,这些患者的完整临床特征,包括治疗和预后、影像学和病理学特征都进行了回顾。3 名男性和 3 名女性,中位年龄为 46 岁(范围 22-56 岁),经病理证实为 CMF-OS。CMF-OS 的影像学表现多样,因此影像学误诊很常见。然而,人们不能忽视恶性影像学表现。最具特征性的病理特征是在软骨黏液样纤维瘤(CMF)样背景下,肿瘤细胞直接产生类骨组织。需要根据 CMF、LGCO、软骨肉瘤(CHS)、常规骨肉瘤(COS)等综合数据进行鉴别诊断。所有患者均接受手术和化疗治疗,1 例患者还接受了放疗。然而,CMF-OS 患者常有复发和转移。CMF-OS 相对侵袭性的生物学行为与该疾病的低级分类相悖。
认识 CMF-OS 并将其与 CMF、CHS、COS 和其他 LGCO 区分开来很重要。尽管 CMF-OS 的分级较低,但预后较差。